WallStSmart
NNVC

NanoViricides Inc

AMEX: NNVC · HEALTHCARE · BIOTECHNOLOGY

$1.49
-0.66% today

Updated 2026-06-04

Market cap
$32.87M
P/E ratio
P/S ratio
EPS (TTM)
$-0.44
Dividend yield
52W range
$1 – $2
Volume
1.0M

NanoViricides Inc (NNVC) Financial statements

SEC filings — annual and quarterly data.

Balance sheet — annual

Item20062007200820092010201120122013201420152016201720182019202020212022202320242025
Total assets$2.73M$1.35M$1.47M$3.00M$8.99M$10.76M$15.63M$16.41M$44.57M$44.19M$36.63M$27.00M$18.55M$13.45M$23.91M$30.26M$23.49M$16.90M$12.82M$8.82M
Cash & equivalents$2.51M$967797.00$816386.00$1.69M$6.96M$9.22M$14.27M$13.92M$36.70M$31.47M$24.16M$15.10M$7.08M$2.56M$13.71M$20.52M$14.07M$8.15M$4.80M$1.56M
Current assets$2.72M$1.22M$1.25M$2.12M$7.46M$9.56M$14.59M$14.52M$37.66M$31.68M$24.38M$15.29M$7.32M$2.83M$13.99M$20.82M$14.42M$8.45M$4.97M$1.67M
Total liabilities$1.49M$849883.00$1.02M$515719.00$2.47M$587176.00$1.78M$8.40M$15.96M$12.40M$13.59M$6.68M$881948.00$2.85M$2.16M$351146.00$412837.00$2.03M$1.36M$1.31M
Current liabilities$574060.00$849883.00$1.02M$515719.00$2.47M$587176.00$1.78M$1.18M$1.23M$600895.00$6.74M$4.67M$881948.00$2.85M$2.16M$351146.00$412837.00$534250.00$1.36M$1.31M
Long-term debt$3.47M$9.04M$7.18M$3.13M$0.00$0.00
Shareholder equity$1.24M$500338.00$443739.00$2.49M$6.52M$10.17M$13.85M$8.01M$28.60M$31.79M$23.05M$20.32M$17.66M$10.60M$21.76M$29.91M$23.08M$14.87M$11.46M$7.52M
Retained earnings$-3.35M$-6.47M$-9.21M$-12.00M$-16.74M$-23.22M$-29.42M$-38.30M$-52.41M$-54.10M$-64.82M$-75.13M$-83.69M$-92.12M$-105.56M$-114.39M$-122.49M$-131.08M$-139.37M$-148.84M
Accounts receivable$58929.00
Inventory$0.00$0.00$0.00$0.00
Goodwill$0.00$0.00$0.00$0.00

Frequently asked questions

How much free cash flow does NNVC generate?

NNVC produced $-8.54M in free cash flow in its most recent fiscal year. Free cash flow is what is left after running and reinvesting in the business, and it is the cash that actually funds buybacks, dividends, and a stronger balance sheet.

Is NNVC's balance sheet healthy?

NNVC holds $1.56M in cash and equivalents against — in long-term debt, on $7.52M of shareholder equity. That debt is best read against the cash flow the business throws off each year.